8-KEarnings & ResultsExhibits & Filings

BIOGEN INC. 8-K Report, Financial Results (Apr 22, 2021)

Filed April 22, 2021For Securities:BIIB

Summary

Biogen Inc. filed an 8-K on April 22, 2021, to report its financial results for the quarter ended March 31, 2021. The core of this filing is the accompanying press release, which provides details on the company's operational and financial performance during the first quarter. Investors should review this press release for specific figures related to revenue, profitability, and other key financial metrics, as these will be crucial in assessing the company's recent performance and future outlook. While the 8-K itself is procedural, referencing the furnished press release is essential. This document serves as the primary source for understanding Biogen's financial health and operational achievements in the period. It's important to note that information furnished under Item 2.02 is not considered "filed" for legal purposes, meaning Biogen does not assume the same liabilities as for formally filed information under Section 18 of the Exchange Act. However, it remains a critical update for investors.

Key Highlights

  • 1Biogen Inc. announced its first-quarter 2021 financial results via press release on April 22, 2021.
  • 2The 8-K filing's primary purpose is to furnish this press release, which contains detailed operational and financial information.
  • 3Investors should consult the furnished press release (Exhibit 99.1) for specific performance data for the quarter ended March 31, 2021.
  • 4The information provided in the press release is furnished and not formally 'filed' for Section 18 liability.
  • 5The filing includes standard exhibits, such as the press release and an interactive data file.

Frequently Asked Questions

The main purpose of this 8-K filing is to officially report Biogen Inc.'s financial results and operational performance for the quarter ended March 31, 2021, through the furnishing of a press release.

The detailed financial results and operational performance data are contained within Biogen's press release, dated April 22, 2021, which is furnished as Exhibit 99.1 to this 8-K filing.

No, information furnished under Item 2.02 of an 8-K, like this press release, is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. This means Biogen does not assume the same liabilities as it would for formally filed documents.

Investors should focus on key financial metrics such as revenue, earnings per share (EPS), profit margins, cash flow, and any specific updates regarding product sales, pipeline developments, or forward-looking guidance provided in the press release for the quarter ended March 31, 2021.